ICOS (Inducible T-cell costimulator) variants and mutations
ICOS (also known as Inducible T-cell costimulator) is a human protein-coding gene encoding an inducible T-cell costimulator protein. It provides costimulatory signals to activated T cells, particularly supporting T-follicular-helper cells, germinal-center responses, and cytokine production. Biallelic loss-of-function variants can cause common-variable-immunodeficiency-like disease with defective antibody responses. This analysis covers 421 ICOS variants and mutations. Of these, 82% have computational variant effect predictions. Disease context includes immunodeficiency, common variable, 1, common variable immunodeficiency, and hypothyroidism. Example ICOS variants include K2*, K2R, and S3P.
Variant analysis overview
- Gene: ICOS
- Protein: Inducible T-cell costimulator
- UniProt accession: Q9Y6W8
- Organism: Homo sapiens
- Variants analyzed: 421
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 209 unspecified-consequence records; 99 missense variants; 82 synonymous variants; 13 frameshift variants; 3 splice-region variants; 10 stop-gained variants; 1 in-frame deletions; 3 stop lost; 1 stop retained variant
- Prediction scores: 347 variants have prediction scores (82% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency, common variable, 1, common variable immunodeficiency, hypothyroidism, severe combined immunodeficiency, combined immunodeficiency, recurrent infections associated with rare immunoglobulin isotypes deficiency, basal cell carcinoma, myxedema, cancer, skin neoplasm, rheumatoid arthritis, immunodeficiency disease.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 2 post-translational modification sites.
- Structural context: 242 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable ICOS variants
Examples include K2*, K2R, S3P, S3S, G4C, G4D, G4V, G4G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- K2* (p.Lys2Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K2R (p.Lys2Arg), gnomAD 2-203936819-A-G, REVEL 0.16, MetaLR 0.16
- S3P (p.Ser3Pro), gnomAD rs1331888922, REVEL 0.01, MetaLR 0.05
- S3S (p.Ser3Ser), rs1360705806, gnomAD 2-203936823-A-C, CADD 5.91
- G4C (p.Gly4Cys), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10032, Variant assessed as somatic; moderate impact.
- G4D (p.Gly4Asp), rs1363456237, TOPMed rs1363456237, gnomAD rs1363456237, REVEL 0.05, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- G4V (p.Gly4Val), gnomAD 2-203936825-G-T, REVEL 0.01, MetaLR 0.03
- G4G (p.Gly4Gly), gnomAD 2-203936826-C-T, CADD 5.62
- L5F (p.Leu5Phe), rs1689659275, ClinGen CA350139428, ClinVar RCV001210135, TOPMed rs1689659275, REVEL 0.03, MetaLR 0.05, Uncertain significance, Immunodeficiency, common variable, 1
- W6* (p.Trp6Ter), rs2469780660, ClinGen CA350139437, ClinVar RCV002824878, CADD 35.00, Pathogenic
- W6R (p.Trp6Arg), TOPMed rs1302371793, gnomAD rs1302371793, REVEL 0.13, MetaLR 0.08
- W6C (p.Trp6Cys), gnomAD 2-203936832-G-C, REVEL 0.06, MetaLR 0.10
- Y7H (p.Tyr7His), TOPMed rs1424893504
- F8L (p.Phe8Leu), rs1689659550, Ensembl rs1689659550, ClinGen CA350139455, ClinVar RCV003066488, Uncertain significance, Immunodeficiency, common variable, 1
- F9V (p.Phe9Val), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10032, Variant assessed as somatic; moderate impact.
- F9F (p.Phe9Phe), rs1689659607, gnomAD 2-203936841-T-C, CADD 12.30
- L10I (p.Leu10Ile), NCI-TCGA Cosmic COSV5702, cosmic curated COSV57029, Variant assessed as somatic; moderate impact.
- F11F (p.Phe11Phe), rs772856321, gnomAD 2-203936847-C-T, CADD 13.60
- C12A (p.Cys12Ala), gnomAD 2-203936847-CT-C, CADD 24.10
- C12F (p.Cys12Phe), gnomAD 2-203936849-G-T, REVEL 0.28, MetaLR 0.35
- L13L (p.Leu13Leu), rs760283528, gnomAD 2-203936851-T-C, CADD 9.06
- R14C (p.Arg14Cys), rs77411896, ClinGen CA2067192, ClinVar RCV000508428, ClinVar RCV001080790, REVEL 0.12, MetaLR 0.03, Benign, not specified; not provided; Immunodeficiency, common variable, 1
- R14H (p.Arg14His), rs776057192, ClinGen CA2067193, cosmic curated COSV57029, ClinVar RCV001890434, REVEL 0.02, MetaLR 0.04, Uncertain significance, Immunodeficiency, common variable, 1
- R14P (p.Arg14Pro), ExAC rs776057192, TOPMed rs776057192, gnomAD rs776057192, REVEL 0.02, MetaLR 0.04, Uncertain significance
- R14S (p.Arg14Ser), 1000Genomes rs77411896, ESP rs77411896, ExAC rs77411896, TOPMed rs77411896, REVEL 0.11, MetaLR 0.06, Benign
- R14L (p.Arg14Leu), gnomAD 2-203936855-G-T, REVEL 0.04, MetaLR 0.02
- R14R (p.Arg14Arg), rs765158675, gnomAD 2-203936856-C-A, CADD 3.01
- I15M (p.Ile15Met), rs762842725, ClinGen CA2067197, ClinVar RCV001245269, ExAC rs762842725, REVEL 0.07, MetaLR 0.06, Uncertain significance, Immunodeficiency, common variable, 1
- I15T (p.Ile15Thr), Ensembl rs907852012
- I15V (p.Ile15Val), rs752669955, ClinGen CA2067196, ClinVar RCV002775062, ExAC rs752669955, REVEL 0.03, MetaLR 0.03, Uncertain significance, Immunodeficiency, common variable, 1
- K16E (p.Lys16Glu), Ensembl rs1581596652, REVEL 0.07, MetaLR 0.04
- V17D (p.Val17Asp), ExAC rs763937343, gnomAD rs763937343
- V17I (p.Val17Ile), TOPMed rs1022059218, REVEL 0.04, MetaLR 0.06
- V17S (p.Val17Ser), gnomAD 2-203936859-T-TA, CADD 22.60
- V17V (p.Val17Val), rs1204325561, gnomAD 2-203936865-T-G, CADD 1.94
- L18S (p.Leu18Ser), ExAC rs751851520, gnomAD rs751851520, REVEL 0.34, MetaLR 0.31
- T19A (p.Thr19Ala), TOPMed rs963826659, REVEL 0.04, MetaLR 0.06
- T19K (p.Thr19Lys), Ensembl rs1689660635, REVEL 0.05, MetaLR 0.12
- T19T (p.Thr19Thr), gnomAD 2-203936871-A-G, CADD 9.01
- G20R (p.Gly20Arg), gnomAD 2-203936872-G-A, REVEL 0.14, MetaLR 0.19
- E21* (p.Glu21Ter), rs1015881666, ClinGen CA63850985, cosmic curated COSV10966, ClinVar RCV001872150, CADD 34.00, Pathogenic
- E21D (p.Glu21Asp), Ensembl rs1690064165
- I22L (p.Ile22Leu), gnomAD 2-203955641-A-C, REVEL 0.04, MetaLR 0.07
- I22V (p.Ile22Val), gnomAD 2-203955641-A-G, REVEL 0.02, MetaLR 0.08
- I22M (p.Ile22Met), gnomAD 2-203955643-C-G, REVEL 0.06, MetaLR 0.12
- N23S (p.Asn23Ser), Ensembl rs1690064207, REVEL 0.06, MetaLR 0.13
- N23N (p.Asn23Asn), rs1248374778, gnomAD 2-203955646-T-C, CADD 9.45
- G24V (p.Gly24Val), rs774325808, ClinGen CA2067216, ClinVar RCV001220471, ClinVar RCV002562508, REVEL 0.08, MetaLR 0.08, Uncertain significance, Immunodeficiency, common variable, 1; Inborn genetic diseases
- G24S (p.Gly24Ser), gnomAD 2-203955647-G-A, REVEL 0.06, MetaLR 0.05
- G24R (p.Gly24Arg), gnomAD 2-203955647-G-C, REVEL 0.04, MetaLR 0.10
- G24G (p.Gly24Gly), gnomAD 2-203955649-T-G, CADD 5.63
- S25P (p.Ser25Pro), gnomAD rs1167660150, REVEL 0.15, MetaLR 0.14
- A26D (p.Ala26Asp), rs761695473, ClinGen CA2067217, ClinVar RCV001043605, ExAC rs761695473, REVEL 0.12, MetaLR 0.15, Uncertain significance, Immunodeficiency, common variable, 1
- N27D (p.Asn27Asp), Ensembl rs761016514
- N27Y (p.Asn27Tyr), Ensembl rs761016514
- N27K (p.Asn27Lys), gnomAD 2-203955658-T-G, REVEL 0.05, MetaLR 0.03
- Y28* (p.Tyr28Ter), gnomAD 2-203955661-T-G, CADD 33.00
- E29D (p.Glu29Asp), Ensembl rs1359375563
- E29K (p.Glu29Lys), rs977088960, ClinGen CA63851010, cosmic curated COSV57030, ClinVar RCV001892154, Uncertain significance, Immunodeficiency, common variable, 1
- M30V (p.Met30Val), gnomAD rs1690064814, REVEL 0.13, MetaLR 0.09
- F31F (p.Phe31Phe), rs147754976, gnomAD 2-203955670-T-C, CADD 9.44
- I32M (p.Ile32Met), ExAC rs756151476, TOPMed rs756151476, gnomAD rs756151476, REVEL 0.01, MetaLR 0.08
- I32V (p.Ile32Val), ExAC rs750601214, TOPMed rs750601214, gnomAD rs750601214, REVEL 0.02, MetaLR 0.04
- I32L (p.Ile32Leu), gnomAD 2-203955671-A-T, REVEL 0.03, MetaLR 0.07
- H34H (p.His34His), rs1380258709, gnomAD 2-203955679-C-T, CADD 6.24
- N35H (p.Asn35His), ExAC rs766442984, gnomAD rs766442984
- N35K (p.Asn35Lys), ESP rs201031378, ExAC rs201031378, TOPMed rs201031378, gnomAD rs201031378, REVEL 0.10, MetaLR 0.04, Likely benign
- N35S (p.Asn35Ser), gnomAD rs1690065211, REVEL 0.05, MetaLR 0.06
- N35Y (p.Asn35Tyr), gnomAD 2-203955680-A-T, REVEL 0.04, MetaLR 0.07
- N35N (p.Asn35Asn), rs201031378, gnomAD 2-203955682-C-T, CADD 3.70
- G36R (p.Gly36Arg), rs202109644, ClinGen CA2067224, ClinVar RCV001064716, ClinVar RCV001815468, REVEL 0.32, MetaLR 0.20, Uncertain significance, not provided; Immunodeficiency, common variable, 1
- G36G (p.Gly36Gly), gnomAD 2-203955685-A-T, CADD 11.30
- G37R (p.Gly37Arg), 1000Genomes rs539709751, ExAC rs539709751, gnomAD rs539709751, REVEL 0.25, MetaLR 0.18
- G37S (p.Gly37Ser), 1000Genomes rs539709751, ExAC rs539709751, gnomAD rs539709751, REVEL 0.22, MetaLR 0.14
- V38V (p.Val38Val), gnomAD 2-203955691-A-T, CADD 6.58
- Q39H (p.Gln39His), NCI-TCGA Cosmic COSV5703, cosmic curated COSV57030, REVEL 0.10, MetaLR 0.14, Variant assessed as somatic; moderate impact.
- L41F (p.Leu41Phe), ExAC rs758752799, gnomAD rs758752799, REVEL 0.06, MetaLR 0.07
- L41I (p.Leu41Ile), gnomAD 2-203955698-T-A, REVEL 0.03, MetaLR 0.06
- K43N (p.Lys43Asn), rs1690065667, ClinGen CA350139701, ClinVar RCV001332934, Ensembl rs1690065667, Uncertain significance, Immunodeficiency, common variable, 1
- K43R (p.Lys43Arg), rs1367837109, ClinGen CA350139698, ClinVar RCV001234328, gnomAD rs1367837109, REVEL 0.02, MetaLR 0.07, Uncertain significance, Immunodeficiency, common variable, 1
- K43E (p.Lys43Glu), gnomAD 2-203955704-A-G, REVEL 0.09, MetaLR 0.06
- P45S (p.Pro45Ser), NCI-TCGA Cosmic COSV5703, cosmic curated COSV57030, REVEL 0.05, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- P45L (p.Pro45Leu), gnomAD 2-203955711-C-T, REVEL 0.07, MetaLR 0.11
- D46E (p.Asp46Glu), ExAC rs780725264, gnomAD rs780725264, REVEL 0.01, MetaLR 0.03
- D46G (p.Asp46Gly), NCI-TCGA Cosmic COSV1003, REVEL 0.02, MetaLR 0.06, Variant assessed as somatic; moderate impact.
- D46V (p.Asp46Val), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10032, Variant assessed as somatic; moderate impact.
- D46Y (p.Asp46Tyr), gnomAD rs1229656377, REVEL 0.07, MetaLR 0.09
- D46N (p.Asp46Asn), gnomAD 2-203955713-G-A, REVEL 0.06, MetaLR 0.06
- I47T (p.Ile47Thr), NCI-TCGA Cosmic COSV5703, cosmic curated COSV57030, Variant assessed as somatic; moderate impact.
- V48A (p.Val48Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V48F (p.Val48Phe), gnomAD 2-203955719-G-T, REVEL 0.14, MetaLR 0.12
- V48V (p.Val48Val), gnomAD 2-203955721-C-T, CADD 5.74
- Q49H (p.Gln49His), NCI-TCGA Cosmic COSV5703, cosmic curated COSV57031, Variant assessed as somatic; moderate impact.
- Q49* (p.Gln49Ter), gnomAD 2-203955722-C-T, CADD 34.00
- Q49Q (p.Gln49Gln), gnomAD 2-203955724-G-A, CADD 3.55
- Q50H (p.Gln50His), 1000Genomes rs55972840, ESP rs55972840, ExAC rs55972840, TOPMed rs55972840, REVEL 0.19, MetaLR 0.12, Benign
- Q50K (p.Gln50Lys), TOPMed rs1254587003, REVEL 0.19, MetaLR 0.16
- Q50P (p.Gln50Pro), gnomAD 2-203955726-A-C, REVEL 0.18, MetaLR 0.18
- Q50Q (p.Gln50Gln), rs55972840, gnomAD 2-203955727-A-G, CADD 8.28
- F51Y (p.Phe51Tyr), ExAC rs769205363, TOPMed rs769205363, gnomAD rs769205363, REVEL 0.08, MetaLR 0.06
- F51L (p.Phe51Leu), gnomAD 2-203955728-T-C, REVEL 0.08, MetaLR 0.04
- M53I (p.Met53Ile), Ensembl rs2105754139, REVEL 0.08, MetaLR 0.05
- M53T (p.Met53Thr), gnomAD 2-203955735-T-C, REVEL 0.11, MetaLR 0.09
- L55L (p.Leu55Leu), rs1291412174, gnomAD 2-203955740-T-C, CADD 7.75
- L56L (p.Leu56Leu), rs1452058252, gnomAD 2-203955745-G-C, CADD 5.39
- K57* (p.Lys57Ter), gnomAD 2-203955746-A-T, CADD 36.00
- G58V (p.Gly58Val), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10032, NCI-TCGA Cosmic COSV5703, Variant assessed as somatic; moderate impact.
- G58W (p.Gly58Trp), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10032, Variant assessed as somatic; moderate impact.
- G58R (p.Gly58Arg), gnomAD 2-203955749-G-A, REVEL 0.15, MetaLR 0.15
- G58G (p.Gly58Gly), gnomAD 2-203955751-G-A, CADD 3.34
- G59R (p.Gly59Arg), NCI-TCGA Cosmic COSV5702, cosmic curated COSV57029, Variant assessed as somatic; moderate impact.
- G59G (p.Gly59Gly), gnomAD 2-203955754-G-T, CADD 0.14
- Q60K (p.Gln60Lys), cosmic curated COSV57031, ExAC rs748772595, gnomAD rs748772595, REVEL 0.01, MetaLR 0.04, Uncertain significance, Inborn genetic diseases
- I61K (p.Ile61Lys), 1000Genomes rs199880572, ExAC rs199880572, gnomAD rs199880572, REVEL 0.07, MetaLR 0.04
- I61L (p.Ile61Leu), gnomAD 2-203955758-A-C, REVEL 0.01, MetaLR 0.04
- I61T (p.Ile61Thr), gnomAD 2-203955759-T-C, REVEL 0.04, MetaLR 0.04
- L62F (p.Leu62Phe), rs886055496, ClinGen CA10612106, cosmic curated COSV10032, ClinVar RCV000344941, Uncertain significance, Immunodeficiency, common variable, 1
- L62P (p.Leu62Pro), Ensembl rs773724499
- L62L (p.Leu62Leu), rs1553499319, gnomAD 2-203955763-C-T, CADD 5.91
- C63* (p.Cys63Ter), rs537195517, ClinGen CA350139839, ClinVar RCV000825033, ClinVar RCV002536038, Pathogenic
- C63Y (p.Cys63Tyr), Ensembl rs1690066694, REVEL 0.26, MetaLR 0.19
- C63S (p.Cys63Ser), gnomAD 2-203955764-T-A, REVEL 0.30, MetaLR 0.18
- C63C (p.Cys63Cys), rs537195517, gnomAD 2-203955766-C-T, CADD 1.91
- D64N (p.Asp64Asn), rs1215466849, ClinGen CA350139842, NCI-TCGA Cosmic COSV5702, cosmic curated COSV57029, REVEL 0.03, MetaLR 0.05, Uncertain significance, Immunodeficiency, common variable, 1
- D64Y (p.Asp64Tyr), gnomAD rs1215466849, REVEL 0.03, MetaLR 0.13, Uncertain significance
- D64H (p.Asp64His), gnomAD 2-203955767-G-C, REVEL 0.05, MetaLR 0.13
- D64D (p.Asp64Asp), gnomAD 2-203955769-T-C, CADD 0.25
- L65F (p.Leu65Phe), gnomAD rs1456585432
- L65L (p.Leu65Leu), rs761713858, gnomAD 2-203955772-C-T, CADD 6.25
- T66I (p.Thr66Ile), TOPMed rs1285221620
- T66A (p.Thr66Ala), gnomAD 2-203955773-A-G, REVEL 0.07, MetaLR 0.08
- K67R (p.Lys67Arg), gnomAD 2-203955777-A-G, REVEL 0.02, MetaLR 0.04
- T68R (p.Thr68Arg), gnomAD 2-203955780-C-G, REVEL 0.10, MetaLR 0.12
- T68T (p.Thr68Thr), rs767276545, gnomAD 2-203955781-A-G, CADD 3.72
- K69E (p.Lys69Glu), ExAC rs773337402, gnomAD rs773337402, REVEL 0.03, MetaLR 0.05
- K69K (p.Lys69Lys), rs1319096476, gnomAD 2-203955784-A-G, CADD 7.07
- G70R (p.Gly70Arg), NCI-TCGA Cosmic COSV5703, cosmic curated COSV57031, REVEL 0.04, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- G70G (p.Gly70Gly), gnomAD 2-203955787-A-G, CADD 6.16
- S71T (p.Ser71Thr), ExAC rs760904375, gnomAD rs760904375, REVEL 0.05, MetaLR 0.04
- S71R (p.Ser71Arg), gnomAD 2-203955790-T-G, REVEL 0.08, MetaLR 0.07
- G72G (p.Gly72Gly), rs766489369, gnomAD 2-203955793-A-G, CADD 3.99
- N73S (p.Asn73Ser), gnomAD 2-203955795-A-G, REVEL 0.03, MetaLR 0.07
- N73N (p.Asn73Asn), gnomAD 2-203955796-C-T, CADD 1.93
- T74K (p.Thr74Lys), TOPMed rs1312547894, gnomAD rs1312547894
- T74R (p.Thr74Arg), TOPMed rs1312547894, gnomAD rs1312547894
- T74S (p.Thr74Ser), gnomAD 2-203955794-AAC-A, CADD 20.60
- T74I (p.Thr74Ile), gnomAD 2-203955798-C-T, REVEL 0.04, MetaLR 0.07
- V75M (p.Val75Met), rs2469807213, ClinVar RCV004560318, Likely benign, EBV-positive nodal T- and NK-cell lymphoma
- V75G (p.Val75Gly), gnomAD 2-203955801-T-G, REVEL 0.16, MetaLR 0.07
- V75V (p.Val75Val), rs753960722, gnomAD 2-203955802-G-T, CADD 0.31
- S76P (p.Ser76Pro), NCI-TCGA Cosmic COSV5702, cosmic curated COSV57029, Variant assessed as somatic; moderate impact.
- I77V (p.Ile77Val), rs1048198057, ClinGen CA63851122, ClinVar RCV001051354, ClinVar RCV002553250, REVEL 0.02, MetaLR 0.06, Uncertain significance, Inborn genetic diseases; Immunodeficiency, common variable, 1
- K78R (p.Lys78Arg), gnomAD 2-203955810-A-G, REVEL 0.02, MetaLR 0.04
- S79R (p.Ser79Arg), rs2105754222, ClinGen CA350139941, ClinVar RCV001947826, Ensembl rs2105754222, REVEL 0.02, MetaLR 0.05, Uncertain significance, Immunodeficiency, common variable, 1
- L80M (p.Leu80Met), ExAC rs765794352, TOPMed rs765794352, gnomAD rs765794352, REVEL 0.06, MetaLR 0.06
- L80R (p.Leu80Arg), Ensembl rs865976515, REVEL 0.05, MetaLR 0.04
- L80L (p.Leu80Leu), rs765794352, gnomAD 2-203955815-C-T, CADD 0.42
- K81E (p.Lys81Glu), TOPMed rs970982033
- K81I (p.Lys81Ile), NCI-TCGA Cosmic COSV5703, cosmic curated COSV57031, Variant assessed as somatic; moderate impact.
- F82L (p.Phe82Leu), NCI-TCGA TCGA novel, NCI-TCGA Cosmic COSV5703, cosmic curated COSV57031, Variant assessed as somatic; moderate impact.
- C83C (p.Cys83Cys), rs555157948, gnomAD 2-203955826-C-T, CADD 1.79
- H84N (p.His84Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- H84H (p.His84His), gnomAD 2-203955829-T-C, CADD 0.14
- S85S (p.Ser85Ser), gnomAD 2-203955832-T-G, CADD 5.83
- Q86R (p.Gln86Arg), TOPMed rs1690068006
- Q86* (p.Gln86Ter), gnomAD 2-203955833-C-T, CADD 33.00
- Q86Q (p.Gln86Gln), gnomAD 2-203955835-G-A, CADD 1.07
- L87I (p.Leu87Ile), gnomAD rs1266149006, REVEL 0.07, MetaLR 0.12
- S88A (p.Ser88Ala), ExAC rs758698963, TOPMed rs758698963, gnomAD rs758698963, REVEL 0.06, MetaLR 0.10
- S88Y (p.Ser88Tyr), cosmic curated COSV57030, TOPMed rs1379505969, gnomAD rs1379505969, REVEL 0.08, MetaLR 0.12
- S88F (p.Ser88Phe), gnomAD 2-203955840-C-T, REVEL 0.08, MetaLR 0.09
- N89D (p.Asn89Asp), gnomAD rs1690068323, REVEL 0.07, MetaLR 0.09
- N89T (p.Asn89Thr), gnomAD 2-203955843-A-C, REVEL 0.08, MetaLR 0.08
- N89S (p.Asn89Ser), gnomAD 2-203955843-A-G, REVEL 0.05, MetaLR 0.06
- N90* (p.Asn90Ter), gnomAD 2-203955844-C-CT, CADD 22.70
- S91G (p.Ser91Gly), rs1314279149, ClinGen CA350140028, ClinVar RCV001244799, TOPMed rs1314279149, REVEL 0.04, MetaLR 0.06, Uncertain significance, Immunodeficiency, common variable, 1
- S91R (p.Ser91Arg), rs1559035890, gnomAD 2-203955848-A-AG, CADD 25.60
- V92V (p.Val92Val), gnomAD 2-203955853-C-T, CADD 5.62
- S93T (p.Ser93Thr), gnomAD rs1209047569, REVEL 0.09, MetaLR 0.11
- S93F (p.Ser93Phe), gnomAD 2-203955855-C-T, REVEL 0.20, MetaLR 0.17
Public ICOS analysis runs
- ICOS analysis run — ICOS (421 variants) — completed 2026-08-20